Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...